Zepbound (tirzepatide) is the FDA-approved anti-obesity formulation of tirzepatide, the same dual GIP/GLP-1 receptor agonist found in Mounjaro. Approved in November 2023 for chronic weight management, it is available in doses from 2.5mg to 15mg administered as a once-weekly injection. Weight Method's compounded tirzepatide is a separate, individualized treatment overseen by your provider; individual results vary and no specific outcome can be promised.
Weight Method offers compounded semaglutide and tirzepatide programs from $199/month with virtual consultations and licensed providers who monitor your progress.
Key Fact
Tirzepatide activates GIP and GLP-1 receptors to reduce appetite. With Weight Method, your provider reviews your health profile, builds an individualized plan, and adjusts dosing based on how you respond over time. Outcomes differ widely from person to person.
Source: Provider-monitored, individualized treatment
Tirzepatide 15mg is a dual GIP/GLP-1 receptor agonist that reduces appetite. Weight Method's compounded tirzepatide is provider-monitored and individualized — results vary by person.
Tirzepatide is a dual GIP/GLP-1 receptor agonist; activating both pathways affects appetite and metabolism. Results differ substantially from person to person depending on starting weight, adherence to lifestyle changes, and individual metabolic factors, and no specific amount of weight loss can be promised. Weight Method provides compounded tirzepatide with comprehensive clinical monitoring at $329/mo; your provider tracks your progress and adjusts your plan throughout treatment.
Early appetite changes within 2-4 weeks at 2.5mg. Visible changes typically emerge over the following months as dosing escalates; the timeline differs by individual.
Early appetite suppression and changes in eating patterns typically begin within 2-4 weeks of starting tirzepatide at 2.5mg. Measurable changes often become evident over the following weeks as the dose escalates into the therapeutic range of 10-15mg. Weight loss generally continues over many months, with the timeline and pace differing from person to person. Weight Method tracks your progress at every stage with regular clinical assessments.
Outcomes vary widely by individual and by the dose tolerated; no specific amount of weight loss can be promised. Your provider sets personalized milestones.
Results with tirzepatide vary widely by individual and by the dose tolerated, and no specific amount of weight loss can be promised. As with all GLP-1 medications, combining treatment with regular exercise and improved nutrition supports better outcomes than medication alone. Your Weight Method provider sets personalized milestones and adjusts your plan based on real-world progress, and is the right source for what you can realistically expect in your situation.
Broad efficacy across patient profiles. Partial GLP-1 responders often improve with dual GIP/GLP-1 activation. Early appetite suppression in weeks 2-6 predicts strong long-term outcomes.
Zepbound's dual-agonist mechanism appears to produce strong responses across a wide range of patient profiles, as demonstrated by the SURMOUNT program's diverse enrollment. Patients who have tried GLP-1-only medications with partial success often see improved results with tirzepatide's added GIP receptor activation. Higher baseline BMI patients achieve larger absolute weight losses, though percentage reductions remain consistent. Early dose tolerance and appetite suppression in weeks 2-6 correlate with strong long-term outcomes. Weight Method's clinical evaluation helps determine if Zepbound's profile matches your health history and weight loss goals.
Take our 2-minute quiz to see if you qualify for GLP-1 treatment.
Start QuizFree consultation. No commitment.